フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function...
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report...
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon...
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) /...
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon...
Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat...
Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V...
Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon...
Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and...
Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host...
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General...
Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease Vivoryon...
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Vivoryon Therapeutics N.V. to Report...
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 Vivoryon Therapeutics N.V. to Hold its 2024 Annual...
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates Vivoryon Therapeutics...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約